METHODS
Data from the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) were used to obtain information on ambulatory care visits of patients with IBD during the years 2003 to 2011. The NAMCS is an annual, cross-sectional survey of office-based outpatient community physicians. Data are collected from office visits to physicians for a randomly assigned 1-week reporting period. NAMCS samples from 112 geographically diverse primary sampling units (PSUs). Within the PSUs, physicians are stratified into specialty groups. The total physician sample is then divided into 52 random subsamples of equal size, and each subsample is assigned a random week in the survey year. A systematic random sample of patient visits during that week is selected by the physician for reporting (varying between 20%-100% of visits depending on the size of the practice). 9 From 2006 to 2011, 1300 to 1500 physicians participated each year, with a physician response rate of approximately 60%. 9, 10 All physician specialties are represented, except anesthesiology, pathology, and radiology. The NHAMCS is an annual cross-sectional survey of hospital-based outpatient visits and emergency department visits. The survey is administered to general hospitals in all 50 states and Washington, DC, but excludes federal and Veterans Affairs (VA) hospitals. Similar to NAMCS, NHAMS also uses 112 PSUs. PSUs are composed of different hospitals and outpatient clinics within the hospitals. Each hospital participates in the survey for a 4-week reporting period once every 15 months. Patient visits to the hospital are randomly sampled, with a goal of 200 patient visits sampled during the period. 9 From 2006 to 2011, 202 to 236 outpatient departments participated each year, with an overall response rate of approximately 73%. 9, 10 Both surveys are administered by the National Center for Health Statistics (NCHS). Data collected for NAMCS and NHAMCS include patient demographics, payment source, health care provider seen, medications prescribed, reasons for visit, diagnoses, services provided, procedures performed, disposition, metropolitan status, geographic region, and facility funding source. Data are available for download on the Centers for Disease Control and Prevention (CDC) Website. 9 These are publicly available data that are anonymous, and as such were deemed exempt from review by the Hamilton Integrated Research Ethics Board.
Our population was identified by searching all encounters for patient diagnoses using an International Classification of Diseases, Ninth Revision, Clinical Modification code for CD (555.*) or UC (556.*). Each ambulatory visit is coded with up to 3 diagnoses. We also obtained data on patient age, sex, race, visit setting, type of physician seen, smoking status, obesity status (.20% above the standard operating weight), and the metropolitan status of the center the patient was seen at. For each visit, prescribed medications (up to 8) were identified using an NCHS 5-digit code. Before 2006, therapeutic drug codes were assigned using codes from the National Drug Code directory. In 2006 and after, drugs were coded using the Lexicon Plus, a proprietary database of Cerner Multum, Inc. 11 A statistical program provided by the CDC was used to convert earlier data to the most recent classification system.
Our drug classes of interest included narcotic analgesics, corticosteroids, and biologicals. The appropriate NCHS codes for narcotic analgesics were defined by searching the New Ambulatory Care Drug Database, which is maintained by the CDC as a search engine for researchers using the NAMCS and NHAMCS databases. 12 For narcotics, we used the database to identify all schedule II, prescription narcotic analgesic drugs used with a frequency of at least 1 in every 10,000 visits. The drug database was also used to search for appropriate corticosteroid codes (excluding inhaled and topical formulations) and biological codes (for all biologicals approved for IBD during 2003-2011, including infliximab, adalimumab, certolizumab, and natalizumab).
Data Analysis
All data were analyzed using SAS 9.4 (SAS Institute, Inc., Cary, NC), and appropriate survey methods were performed using the SUDAAN software package. Because of the complex methodology of NAMCS and NHAMCS, a sample weight is applied to each patient visit that factors in many variables. This permits survey data to be inflated and produce unbiased annual national estimates. Weights are calculated based on 4 main factors: inflation by reciprocals of selection probabilities, adjustment for nonresponse, population ratio adjustments, and weight smoothing. 13 The span of 2003 to 2011 was divided into 3 time periods, and descriptive statistics were used to examine the baseline characteristics of patients with IBD in each of these periods (2003-2005, 2006-2008, and 2009-2011) . Univariate analyses with the chi-square test statistic were then used to determine whether there was a significant change in the proportion of patients with IBD treated with narcotic analgesics, corticosteroids, and biologicals between the 3 time periods. Univariate analyses were performed to look for significant associations between potential risk factors and the likelihood of receiving a prescription for narcotic analgesics or corticosteroids for patients with IBD over the entire study period. Dichotomous variables were analyzed using the chi-squared test, and continuous variables were analyzed using the student's t test.
RESULTS
From 2003 to 2011, a total of 1119 patients with IBD had visits recorded in the NAMCS and NHAMCS databases. Baseline demographic and covariates were relatively similar between each of the 3 time periods studied ( Table 1 Corticosteroid prescriptions for only systemic steroids (budesonide excluded) was also assessed, but no significant change in prescriptions was seen over the 3 time periods among all patients with IBD (P ¼ 0.24), CD only (P ¼ 0.45), or UC only (P ¼ 0.27). Patients using biological therapies were less likely to receive corticosteroids (P ¼ 0.03) or narcotics (,0.0001) compared with patients who were not using biological therapies. As discussed in the methods, patient weights for each visit allowed for approximation of national estimates of number of visits for patients with IBD for each of the 3 time periods (Table 2) .
Assessment of risk factors predicting narcotic or corticosteroid prescriptions can be seen in Table 3 . Odds ratios (ORs) calculated are adjusted for prespecified patient weights within NAMCS and NHAMCS, to reflect a national estimate of the frequency of occurrence. Patients seen by medicine subspecialists were less likely to receive narcotics compared with patients seen by primary care physicians or surgical specialists (OR 0.38, 95% confidence interval [CI], 0.13-1.11; P ¼ 0.02). There was no relationship between narcotic prescriptions and metropolitan status, reason for visit, obesity, tobacco use, and race. The median time spent with physicians for patients with IBD was 20 minutes. The median time spent was used as a threshold to determine whether time spent was associated with narcotic prescription. A trend was seen toward less narcotic prescriptions, if 20 minutes or more was spent with a patient (OR 0.50, 95% CI, 0.18-1.38; P ¼ 0.10); but, this was not statistically significant. There was no relationship between corticosteroid prescriptions and any of the risk factors examined, although there was a trend toward receiving corticosteroids if the major reason for visit was considered a flareup of a chronic problem (OR 2.04, 95% CI, 1.08-3.85; P ¼ 0.08).
DISCUSSION
Because of the efficacy of biological therapies in IBD, we expected to observe an increase in use with a corresponding decrease in stopgap therapies such as corticosteroids and narcotics. Our study reveals that although prescriptions for biologicals have increased almost 5-fold from 2003 to 2005 to 2009 to 2011, there was no significant change in prescriptions for corticosteroids or narcotics. The increase in biological prescriptions was mainly driven by patients with CD. These trends in biological and corticosteroid prescriptions are consistent with other experiences in the literature. Dramatic increases in tumor necrosis factor-alpha (TNFa) antagonist use have been reported in France and Germany. 14, 15 A large population-based study from the United Kingdom examined prescription trends over 20 years and found that oral steroid prescriptions increased from the levels observed between 1990 and 1993, as compared with the periods from 2002 to 2005 and 2006 to 2010 and have remained stable since 2010. They did, however, find that prolonged steroid use and repeated steroid exposure declined in CD; but, both of these significantly increased in UC patients. 16 A health claims database study from Northern California similarly found that prescriptions for corticosteroids in CD did not decline between 1998 and 2005, but there was a decline of 36% in prolonged steroid exposure during this time. 17 However, for UC, there was an increase of 44% in prescriptions for oral corticosteroids, and similar to the United Kingdom study, prolonged steroid exposure also increased by 27%. 17 Among pediatric patients with IBD in Finland, corticosteroid prescriptions were constant when comparing the 7-year period of 1999 to 2005 with 2008 and 2009. 18 Recent studies have alerted the public regarding an exponential increase of narcotic use in the United States, leading to many complications including addiction-and opioid-related deaths. 7, 8, 19, 20 Patients with IBD in North America are commonly prescribed narcotics. 4, 21, 22 A population-based study from Manitoba reported 5% of patients with IBD became heavy opioid users within 10 years of diagnosis and are almost 3 times more likely than patients withouht IBD to be heavy users. 4 A large US Medicaid database study reported patients with IBD had almost twice the odds (OR 1.81, 95% CI, 1.79-1.84) for using narcotics compared with the general population. 22 Our study is the first to examine trends in narcotic use over time in IBD patients and despite the availability of more effective therapies for IBD, narcotic prescriptions remained stable over the time periods examined. Medicine subspecialists were less likely to provide narcotics compared with primary care physicians or surgical specialists, and there was a trend for narcotics to be prescribed less when patient visit times were 20 minutes or more. This may suggest narcotics are more likely to be prescribed in acute care settings (such as emergency departments or urgent care centers), where visit times tends to be shorter, or during surgical outpatient visits (such as postoperative follow-up).
There could be many possibilities for the patterns observed in this study. Despite the availability of more effective biological therapies, patients with IBD have relapses of disease and often present to primary care physicians or emergency departments. Corticosteroids and narcotics are easy to prescribe, affordable, and can provide symptom relief to patients quickly. Biologicals are often prescribed only by subspecialists, and delays in initiation often occur because of the need for prerequisite testing (for latent tuberculosis or hepatitis B) or obtaining insurance approval for coverage. This may explain why prescriptions for corticosteroids remain constant, as they are being used early in the treatment of flares, but with subsequent plans to transition patients to immunomodulators or biological therapies. This would also explain why prolonged steroid exposure in CD has been declining, despite the lack of change in steroid prescriptions. 16, 17 Our results also support that once patients are using biological therapies, they are less likely to receive corticosteroids or narcotics compared with those patients not using biologicals. The increases in prolonged steroid use for UC reported in multiple studies may reflect the delayed introduction of biologicals to market for UC as compared with CD. 16, 17 Another possible reason for the patterns observed in this study is that biological therapies have yet to achieve the critical mass needed before noticeable reductions can be observed in corticosteroids and narcotics.
Strengths of using the NAMCS and NHAMCS databases are they permit examination of trends in ambulatory care over time. The surveys provide relatively recent data obtained over a wide geographic and demographic range. Given their complex sampling design with targeted oversampling of important populations (such as racial/ethnic minorities), the surveys can provide a truly national representation of the U.S. ambulatory care system. To achieve this, statistical analyses are performed using prespecified visit weights that are designed to reflect true national estimates of patient visits. These weights account for the inverse probability of selection inherent in survey studies because of nonresponse, among other factors, and are used to expand the survey estimates to the national level. In doing so, the generalizability of the survey results is increased.
An important limitation to using the NAMCS and NHAMCS databases is the lack of certain clinical information; for example, severity of illness. This limits our ability to correlate prescribing practices with provider intent. For example, although we can ascertain whether a patient with IBD received narcotics at a visit, we do not know for certain whether the narcotic was prescribed to treat severe pain from a CD flare or prescribed for some other pathology. Similarly, results of any radiologic and laboratory testing that was ordered during a visit are not available through NAMCS and NHAMCS, which limits conclusions we can make about how certain diagnostics might affect prescribing patterns. Without individual patient or provider identifiers, the visit-level information in these databases also does not allow for longitudinal analysis. One further limitation to our study is that we did not examine trends within each category of medication used. For instance, although corticosteroid prescriptions did not decline over the period examined, a shift from using oral prednisone to budesonide in CD could lead to less corticosteroid-related adverse events.
Although common, the use of International Classification of Diseases, Ninth Revision coding to identify our cohort also represents an important limitation, as administrative coding is subject to error. The International Classification of Diseases, Ninth Revision coding for CD and UC has not changed in recent years, nor has there been any change in the criteria for diagnosis of CD or UC, which helps minimize any effect that this may have. This method of identifying patients with IBD using the NAMCS and NHAMCS databases has also been used previously. 23 There is also a limitation in our use of NCHS-assigned codes to identify specific medications. Previous studies have taken different approaches to the task of medication identification. A 2009 study looking at only corticosteroid and immunomodulator use among patients with IBD employed the more broadly applicable 4-digit National Drug Code directory identifiers for these medication classes. 23 We chose to use the NCHS 5-digit identifier provided by the CDC drug database search engine to provide a more specific estimate of the medications in the classes of interest that would be prescribed to patients with IBD. In summary, this study demonstrated trends in prescriptions provided to patients with IBD in the United States from 2003 to 2011. Despite a significant increase in biological prescriptions, prescriptions for corticosteroids and narcotics have remained stable. There is a need for further research to determine characteristics of patients who continue to receive narcotics and corticosteroids. This could lead to the introduction of targeted interventions, such as financial assistance programs, toward patients at risk in an attempt to reduce the risk of poor outcomes. Medical specialists need to work closely with primary care physicians and surgeons to improve access to care for patients with IBD. The development of care treatment algorithms for expedited referral in patients with acute flares of disease could help minimize prolonged exposure of these medications. Implementing prescribing restrictions to the use of corticosteroids and narcotics could also lead to less prolonged use and abuse. 24 
